MX2012005358A - Procedimiento para la preparacion de etexilato de dabigatran. - Google Patents
Procedimiento para la preparacion de etexilato de dabigatran.Info
- Publication number
- MX2012005358A MX2012005358A MX2012005358A MX2012005358A MX2012005358A MX 2012005358 A MX2012005358 A MX 2012005358A MX 2012005358 A MX2012005358 A MX 2012005358A MX 2012005358 A MX2012005358 A MX 2012005358A MX 2012005358 A MX2012005358 A MX 2012005358A
- Authority
- MX
- Mexico
- Prior art keywords
- dabigatran etexilate
- producing
- producing dabigatran
- etexilate
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
Se describe un procedimiento mejorado para la preparación de etexilato de dabigatran, así como de compuestos análogos de la fórmula 7. (ver fórmula (7)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09176369 | 2009-11-18 | ||
PCT/EP2010/066959 WO2011061080A1 (de) | 2009-11-18 | 2010-11-06 | Verfahren zur herstellung von dabigatran etexilat |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012005358A true MX2012005358A (es) | 2012-05-29 |
Family
ID=41683288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012005358A MX2012005358A (es) | 2009-11-18 | 2010-11-06 | Procedimiento para la preparacion de etexilato de dabigatran. |
Country Status (19)
Country | Link |
---|---|
US (2) | US8399678B2 (es) |
EP (1) | EP2501692B1 (es) |
JP (1) | JP5746707B2 (es) |
KR (1) | KR101802132B1 (es) |
CN (1) | CN102612517B (es) |
AR (1) | AR079055A1 (es) |
AU (1) | AU2010321098B2 (es) |
BR (1) | BR112012011689B8 (es) |
CA (1) | CA2780715C (es) |
CL (1) | CL2012001171A1 (es) |
DK (1) | DK2501692T3 (es) |
EA (1) | EA023117B1 (es) |
ES (1) | ES2525112T3 (es) |
IL (1) | IL219247A (es) |
MX (1) | MX2012005358A (es) |
NZ (1) | NZ599587A (es) |
PL (1) | PL2501692T3 (es) |
TW (1) | TWI478912B (es) |
WO (1) | WO2011061080A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
EP2288335A1 (en) * | 2008-03-28 | 2011-03-02 | Boehringer Ingelheim International GmbH | Process for preparing orally administered dabigatran formulations |
EP2297132B1 (de) * | 2008-06-16 | 2015-02-25 | Boehringer Ingelheim International GmbH | Verfahren zur herstellung eines zwischenprodukts von dabigatran etexilate |
TWI436994B (zh) * | 2008-07-14 | 2014-05-11 | Boehringer Ingelheim Int | 製備含有達比加群(dabigatran)之藥物組合物的新穎方法 |
NZ592616A (en) | 2008-11-11 | 2013-04-26 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
SG10201407718WA (en) | 2009-11-18 | 2015-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
EP2522662A1 (en) | 2011-05-11 | 2012-11-14 | Medichem, S.A. | Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers |
EP2834224B1 (en) | 2012-04-02 | 2018-06-06 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
CN102850326B (zh) * | 2012-06-19 | 2014-04-09 | 上海现代制药股份有限公司 | 一种达比加群酯中间体及其制备方法和应用 |
CN102850327B (zh) * | 2012-06-19 | 2014-07-16 | 上海现代制药股份有限公司 | 一种制备达比加群酯的中间体及其制备方法和应用 |
CN102850325B (zh) * | 2012-06-19 | 2014-03-26 | 上海现代制药海门有限公司 | 一种达比加群酯关键中间体的制备方法 |
US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
CA2907839C (en) * | 2013-03-25 | 2021-11-23 | Usv Limited | Synthesis of dabigatran |
CN103224469A (zh) * | 2013-05-16 | 2013-07-31 | 上海应用技术学院 | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 |
CN103288744A (zh) * | 2013-06-04 | 2013-09-11 | 上海应用技术学院 | 一种含氟基团修饰的达比加群酯类似物及其合成方法 |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN104418805B (zh) * | 2013-09-11 | 2017-02-22 | 浙江海正药业股份有限公司 | 一种达比加群酯中间体及其制备方法和应用 |
CN104003977B (zh) * | 2014-06-05 | 2016-04-13 | 雅本化学股份有限公司 | N-(2-氯甲基-1-甲基-1h-苯并咪唑-5-酰基)-n-(吡啶-2-基) -3-氨基丙酸乙酯的制备方法 |
WO2016000230A1 (zh) | 2014-07-03 | 2016-01-07 | 上海医药工业研究院 | 一种达比加群酯中间体的制备方法及中间体化合物 |
CN105461688B (zh) * | 2014-08-26 | 2017-12-29 | 上海医药工业研究院 | 苯并咪唑化合物k的合成方法 |
CN105523999B (zh) * | 2014-10-21 | 2020-04-24 | 重庆医药工业研究院有限责任公司 | 一种达比加群酯中间体的合成方法 |
CN104447697B (zh) * | 2014-11-24 | 2016-08-24 | 蚌埠丰原医药科技发展有限公司 | 一种达比加群酯中间体的制备方法 |
CN104910047B (zh) * | 2015-05-11 | 2017-06-06 | 常州市阳光药业有限公司 | 达比加群酯中间体的制备方法 |
CN104987323B (zh) * | 2015-07-10 | 2017-08-22 | 浙江美诺华药物化学有限公司 | 一种达比加群酯的制备方法 |
CN106554370A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 含有磷酸酯的达比加群衍生物及其制备方法和用途 |
CN105348148B (zh) * | 2015-11-30 | 2017-12-26 | 山东新华制药股份有限公司 | 制备达比加群酯中间体缩合物的杂质的草酸盐的方法 |
CN105566296A (zh) * | 2015-12-16 | 2016-05-11 | 蚌埠丰原医药科技发展有限公司 | 一种制备达比加群酯酰胺化杂质的方法 |
CN105669651B (zh) * | 2016-03-07 | 2018-03-06 | 山东罗欣药业集团股份有限公司 | 一种甲磺酸达比加群酯的制备工艺 |
CN105732433A (zh) * | 2016-04-13 | 2016-07-06 | 山东新华制药股份有限公司 | 达比加群酯中间体缩合物的精制方法 |
CN105777622A (zh) * | 2016-04-13 | 2016-07-20 | 山东新华制药股份有限公司 | 制备达比加群酯中间体环化物的杂质的方法 |
CN106083822B (zh) * | 2016-08-17 | 2018-09-11 | 本溪经济开发区博美医药新技术开发有限公司 | 一种甲磺酸达比加群酯中间体的制备方法 |
CN106928195B (zh) * | 2017-03-29 | 2019-04-19 | 福建省微生物研究所 | 一种达比加群酯关键中间体的合成方法 |
CN108373466B (zh) * | 2018-04-16 | 2020-04-10 | 宏冠生物药业有限公司 | 一种达比加群酯的制备方法 |
CN108640903A (zh) * | 2018-04-16 | 2018-10-12 | 宏冠生物药业有限公司 | 一种达比加群酯中间体的制备方法 |
CN108997316A (zh) * | 2018-08-17 | 2018-12-14 | 四川青木制药有限公司 | 一种达比加群酯的制备工艺 |
CN111606885A (zh) * | 2020-06-18 | 2020-09-01 | 安徽鼎旺医药有限公司 | 一种达比加群酯甲磺酸盐及其制备方法 |
CN114380797A (zh) * | 2021-12-27 | 2022-04-22 | 山东诚汇双达药业有限公司 | 一种达比加群酯的合成方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
AU2300699A (en) | 1998-02-17 | 1999-08-30 | Ono Pharmaceutical Co. Ltd. | Amidino derivatives and drugs containing the same as the active ingredient |
US6242466B1 (en) * | 1998-07-23 | 2001-06-05 | Boehringer Ingelheim Pharma Kg | Substituted phenylamidines |
DE19833105A1 (de) * | 1998-07-23 | 2000-01-27 | Boehringer Ingelheim Pharma | Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
EP1609784A1 (de) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
DE102005061624A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
DE102005061623A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
EP1956018A1 (de) | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung eines Benzimidazolderivats |
EP2288335A1 (en) | 2008-03-28 | 2011-03-02 | Boehringer Ingelheim International GmbH | Process for preparing orally administered dabigatran formulations |
CA2716642C (en) | 2008-03-28 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Method for manufacturing acid pellets |
EP2300431B1 (en) | 2008-06-16 | 2016-01-06 | Boehringer Ingelheim International GmbH | Process for the manufacture of an intermediate in the synthesis of dabigatran |
EP2297132B1 (de) | 2008-06-16 | 2015-02-25 | Boehringer Ingelheim International GmbH | Verfahren zur herstellung eines zwischenprodukts von dabigatran etexilate |
TWI436994B (zh) | 2008-07-14 | 2014-05-11 | Boehringer Ingelheim Int | 製備含有達比加群(dabigatran)之藥物組合物的新穎方法 |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
-
2010
- 2010-11-04 US US12/939,521 patent/US8399678B2/en active Active
- 2010-11-06 PL PL10773338T patent/PL2501692T3/pl unknown
- 2010-11-06 JP JP2012539262A patent/JP5746707B2/ja active Active
- 2010-11-06 WO PCT/EP2010/066959 patent/WO2011061080A1/de active Application Filing
- 2010-11-06 CN CN201080052215.8A patent/CN102612517B/zh active Active
- 2010-11-06 AU AU2010321098A patent/AU2010321098B2/en active Active
- 2010-11-06 ES ES10773338.8T patent/ES2525112T3/es active Active
- 2010-11-06 BR BR112012011689A patent/BR112012011689B8/pt active IP Right Grant
- 2010-11-06 KR KR1020127012713A patent/KR101802132B1/ko active IP Right Grant
- 2010-11-06 MX MX2012005358A patent/MX2012005358A/es active IP Right Grant
- 2010-11-06 EA EA201200741A patent/EA023117B1/ru not_active IP Right Cessation
- 2010-11-06 DK DK10773338.8T patent/DK2501692T3/da active
- 2010-11-06 NZ NZ599587A patent/NZ599587A/en unknown
- 2010-11-06 EP EP10773338.8A patent/EP2501692B1/de active Active
- 2010-11-06 CA CA2780715A patent/CA2780715C/en active Active
- 2010-11-17 AR ARP100104246A patent/AR079055A1/es active IP Right Grant
- 2010-11-17 TW TW099139596A patent/TWI478912B/zh active
-
2012
- 2012-04-18 IL IL219247A patent/IL219247A/en active IP Right Grant
- 2012-05-04 CL CL2012001171A patent/CL2012001171A1/es unknown
-
2013
- 2013-02-15 US US13/768,350 patent/US8993770B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2780715A1 (en) | 2011-05-26 |
EA201200741A1 (ru) | 2013-02-28 |
US8399678B2 (en) | 2013-03-19 |
AU2010321098B2 (en) | 2016-06-09 |
AR079055A1 (es) | 2011-12-21 |
BR112012011689B8 (pt) | 2021-05-25 |
NZ599587A (en) | 2014-06-27 |
CL2012001171A1 (es) | 2012-08-10 |
CA2780715C (en) | 2017-09-12 |
TWI478912B (zh) | 2015-04-01 |
JP2013511482A (ja) | 2013-04-04 |
TW201129555A (en) | 2011-09-01 |
CN102612517A (zh) | 2012-07-25 |
IL219247A (en) | 2014-11-30 |
EP2501692B1 (de) | 2014-09-03 |
KR101802132B1 (ko) | 2017-11-28 |
BR112012011689B1 (pt) | 2021-05-04 |
WO2011061080A1 (de) | 2011-05-26 |
ES2525112T3 (es) | 2014-12-18 |
US8993770B2 (en) | 2015-03-31 |
EP2501692A1 (de) | 2012-09-26 |
EA023117B1 (ru) | 2016-04-29 |
CN102612517B (zh) | 2014-09-17 |
IL219247A0 (en) | 2012-06-28 |
KR20120099039A (ko) | 2012-09-06 |
US20130158270A1 (en) | 2013-06-20 |
PL2501692T3 (pl) | 2015-03-31 |
US20110275824A1 (en) | 2011-11-10 |
BR112012011689A2 (pt) | 2015-10-13 |
DK2501692T3 (da) | 2014-12-08 |
JP5746707B2 (ja) | 2015-07-08 |
AU2010321098A1 (en) | 2012-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012005358A (es) | Procedimiento para la preparacion de etexilato de dabigatran. | |
UA104438C2 (uk) | Спосіб одержання дабігатрану і його проміжних сполук | |
MX2012004114A (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
ZA201004848B (en) | Method for the production of disubstituted imidazolium salts | |
MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
UA115136C2 (uk) | Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1 | |
MY162933A (en) | Chemical compounds | |
WO2010102980A9 (en) | Process for preparing substituted 2-nitrobiphenyls | |
IL208371A0 (en) | Method for producing an intermediate product of dabigatran etexilate | |
EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
MY163339A (en) | A method of producing ingenol-3-angelate | |
MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
GEP20135960B (en) | New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof | |
MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
CL2012000493A1 (es) | Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. | |
MX2010004592A (es) | Metodo mejorado para producir diesteres. | |
HK1124842A1 (en) | Methods of preparing imidazole-based compounds | |
WO2008075205A3 (en) | Improved process for the preparation of voriconazole | |
MX2011013790A (es) | Derivados de flavina. | |
UA110332C2 (en) | Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea | |
MX2007013872A (es) | Procedimiento para la produccion de 4-bifenililazetidina-2-onas. | |
WO2012082942A3 (en) | Neuropeptide analogs, compositions, and methods for treating pain | |
MY160625A (en) | Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation | |
CY1110944T1 (el) | Νεα παραγωγα κυκλοαλκυλιωμενων βενζοθειαδιαζινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |